Since the February update, an additional 5 patients have been dosed, resulting in 2 Complete Responses (CR) and 3 Partial ...

Researchers sought to determine whether dual-targeted CAR-T therapy would be effective for patients with relapsed or refractory MCL.

Imugene continues to actively enrol patients into the Phase 1b azer-cel trial at ten US sites with up to six sites in ...

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...

In a new innovative and groundbreaking medical achievement, Abu Dhabi Stem Cells Centre (ADSCC) has manufactured the UAE's ...

My pediatrician got me an appointment at Memorial Sloan Kettering, the top hospital in New York for cancer treatment. There, the doctors ran me through scans. They found a tumor the size of a ...

Mantle cell lymphoma treatment offers options if patients relapse after CAR T-cell therapy, from bispecific antibodies, antibody drug conjugates, and other emerging therapies.

Explore the latest advancements in immunotherapies for T-cell lymphoma, addressing unique challenges and promising new ...

Non-hodgkin's Lymphoma Pipeline constitutes 200+ key companies continuously working towards developing 220+ Non-hodgkin's Lymphoma treatment therapies, analyzes DelveInsight.

In July 2020, Monjuvi in combination with lenalidomide received FDA approval for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise ...

During a live event, Priyanka Pophali, MD, MBBS, discussed CAR T-cell therapy referrals, timing, and challenges in relapsed ...